ESMO 2022 Conference Coverage
ESMO 2022 Updated Results From ADAURA: Osimertinib as Adjuvant Therapy in Patients With Resected EGFRm Stage IB–IIIA NSCLC
By
ESMO 2022 Conference Coverage
FEATURING
Tom John
By
ESMO 2022 Conference Coverage
FEATURING
Tom John
Comments 0
Login to view comments.
Click here to Login
